E-viri
Recenzirano
Odprti dostop
-
Ye, Lan; Greten, Stephan; Wegner, Florian; Doll-Lee, Johanna; Krey, Lea; Heine, Johanne; Gandor, Florin; Vogel, Annemarie; Berger, Luise; Gruber, Doreen; Levin, Johannes; Katzdobler, Sabrina; Peters, Oliver; Dashti, Eman; Priller, Josef; Spruth, Eike Jakob; Kühn, Andrea A.; Krause, Patricia; Spottke, Annika; Schneider, Anja; Beyle, Aline; Kimmich, Okka; Donix, Markus; Haussmann, Robert; Brandt, Moritz; Dinter, Elisabeth; Wiltfang, Jens; Schott, Björn H.; Zerr, Inga; Bähr, Mathias; Buerger, Katharina; Janowitz, Daniel; Perneczky, Robert; Rauchmann, Boris-Stephan; Weidinger, Endy; Düzel, Emrah; Glanz, Wenzel; Teipel, Stefan; Kilimann, Ingo; Wurster, Isabel; Brockmann, Kathrin; Hoffmann, Daniel C.; Klockgether, Thomas; Krause, Olaf; Heck, Johannes; Höglinger, Günter U.; Klietz, Martin
Journal of neurology, 05/2024, Letnik: 271, Številka: 5Journal Article
Background Multiple system atrophy (MSA) is a complex and fatal neurodegenerative movement disorder. Understanding the comorbidities and drug therapy is crucial for MSA patients’ safety and management. Objectives To investigate the pattern of comorbidities and aspects of drug therapy in MSA patients. Methods Cross-sectional data of MSA patients according to Gilman et al. (2008) diagnostic criteria and control patients without neurodegenerative diseases (non-ND) were collected from German, multicenter cohorts. The prevalence of comorbidities according to WHO ICD-10 classification and drugs administered according to WHO ATC system were analyzed. Potential drug-drug interactions were identified using AiDKlinik®. Results The analysis included 254 MSA and 363 age- and sex-matched non-ND control patients. MSA patients exhibited a significantly higher burden of comorbidities, in particular diseases of the genitourinary system. Also, more medications were prescribed MSA patients, resulting in a higher prevalence of polypharmacy. Importantly, the risk of potential drug-drug interactions, including severe interactions and contraindicated combinations, was elevated in MSA patients. When comparing MSA-P and MSA-C subtypes, MSA-P patients suffered more frequently from diseases of the genitourinary system and diseases of the musculoskeletal system and connective tissue. Conclusions MSA patients face a substantial burden of comorbidities, notably in the genitourinary system. This, coupled with increased polypharmacy and potential drug interactions, highlights the complexity of managing MSA patients. Clinicians should carefully consider these factors when devising treatment strategies for MSA patients.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.